Increasing incidence of cancer cases around the globe to drive the growth of global leukemia therapeutics market.
According to TechSci Research report, “Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Sex (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Company, By Region, Forecast & Opportunities, 2026”, the global leukemia therapeutics market is expected to grow at a formidable rate during the forecast period to reach USD7636.21 million on account of the increasing prevalence of leukemia. Furthermore, strong developing drug pipeline, increasing approvals of novel & innovative drugs and immunotherapies are projected to spur the market during forecast years. Moreover, technological advancements & innovations and faster approvals by the regulatory agencies are further creating lucrative opportunities for the market. However, lack of awareness among the population pertaining to the disease and its severity can hamper the growth of market during forecast period. Additionally, presence of generic drugs and limited availability of treatment options restrict the growth of market during the forecast period. Furthermore, lack of early diagnosis of the disease also obstructs the market growth over the next few years. Moreover, the high cost of treatments and associated adverse effects are further slowing down the growth of market.
Browse 158 Figures spread through 110 Pages and an in-depth TOC on“ Global Leukemia Therapeutics Market”
The global leukemia therapeutics market is segmented based on type, gender, age groups, diagnosis, treatment, drugs, route of administration, country, company and region. Based on type, the market can be divided into chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and others. The chronic lymphocytic leukemia is expected to dominate the market on account of the large number of treatment options available and high incidence rate of chronic lymphocytic leukemia. Based on age groups, the market can be segmented into 0-15, 15-30, 30-50 and 50+. The 50+ years age group segment is expected to dominate the market since leukemia mostly affects the old age population. Based on sex, the market can be bifurcated into male and female. The male segment dominates the market since male population especially in their middle age are affected by this disease. Leukemia is often regarded as the most common type of cancer in males. Based on treatment, the market can be categorized into chemotherapy, stem cell transplantation, immunotherapy, targeted therapy and others. The chemotherapy segment is expected to dominate the market during forecast period due to its effectiveness in killing cancerous cells and inhibiting their proliferation and maintaining a normal level of lymphocytes. Additionally, increased survival rate of the patients treated with chemotherapy is again fueling the demand for the segment. The immunotherapy segment is expected to register the highest growth during the forecast period. Based on drug, the market can be segmented into antimetabolites, hormones (corticosteroids), tyrosine kinase inhibitors, monoclonal antibodies and others. The tyrosine kinase inhibitors hold the largest market share and this can be ascribed to their fewer side effects and higher efficacy.
Novartis AG, AbbVie Inc., Roche Holding AG, Amgen Inc., AstraZeneca PLC, Pfizer Inc., Merck & Company Inc., Eli Lilly and Company Ltd., Bristol-Myers Squibb Company, Gilead Sciences Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd., Stemline Therapeutics Inc., Icell Gene Therapeutics, Otsuka Holdings Company Ltd. are some of the leading players operating in global leukemia therapeutics market. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in May 2018, Novartis launched its CAR-T cell therapy for the second indication treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma. With the innovative launch of Kymriah CAR-T cell therapy, Novartis is now a pioneer of leukemia immunotherapies. Recently on February 2021, Novartis has received a designation from FDA for breakthrough therapy for ongoing investigations on STAMP inhibitor Asciminib (ABL001) for chronic myeloid leukemia.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4534
Customers can also request for 10% free customization on this report.
“Asia-Pacific is expected to witness the highest growth in the leukemia therapeutics market during the forecast period on account of the increasing investments in research and development for the treatment of leukemia and the growing prevalence of leukemia in countries such as Japan and India. Additionally, the increasing disposable income of consumers and improving healthcare infrastructure in the region is further expected to propel the market during forecast period. Also, growing focus of market players on addressing healthcare-based demands in these countries is further expected to foster the growth of market through 2026.”, said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Company, By Region, Forecast & Opportunities, 2026” has evaluated the future growth potential of global leukemia therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global leukemia therapeutics market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017